Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer

• Status: Active, not recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The study will evaluate the clinical activity of nivolumab in combination with 3 separate investigational agents, glesatinib, sitravatinib, or mocetinostat.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mirati Therapeutics Inc.
• Treatments: Antibodies, Monoclonal; Mocetinostat; Nivolumab

Criteria

Inclusion Criteria:

• Diagnosis of non-small cell lung cancer.

• Prior treatment with a checkpoint inhibitor (as appropriate per cohort)

• Adequate bone marrow and organ function

Exclusion Criteria:

• Uncontrolled tumor in the brain

• Unacceptable toxicity with prior checkpoint inhibitor

• Impaired heart function